Drawing for PLACON THERAPEUTICS

USPTO serial 86832158

PLACON THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
โ€”
Examiner
RHIM, ANDREW
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PLACON THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jenevieve Maerker,

JENEVIEVE MAERKER, FOLEY HOAG LLP155 SEAPORT BOULEVARDBOSTON, MA 02210-2600UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, namely, antineoplastics, anti-inflammatories, anti-infectives, antibacterial pharmaceuticals, antibiotics, antifungal preparations, antivirals, cardiovascular pharmaceuticals, dermatological pharmaceutical products, inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders, pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases, pharmaceutical preparations for the treatment and prevention of diseases and disorders of the auto-immune system, the metabolic system, the musculo-skeletal system and the genitourinary system, pharmaceutical preparations for use in hematology and in tissue and organ transplantation, pharmaceutical preparations for the treatment of eye diseases and conditions, pharmaceutical preparations for the treatment of heart rhythm disorders, pharmaceutical preparations for the treatment of immune system related diseases and disorders, pharmaceutical preparations for the treatment of kidney diseases, pharmaceutical preparations for treating diabetes, pharmaceutical preparations for treating hypertension, pharmaceutical preparations for treating skin disorders, pharmaceutical preparations for use in dermatology, pharmaceutical preparations for use in urology, pharmaceutical products for ophthalmological use, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical products for the treatment of bone diseases, pharmaceutical products for treating respiratory diseases, pharmaceutical products for treating respiratory diseases and asthma, pharmaceutical preparations for the treatment of sleep disorders and neurological disordersACTIVEโ€”

Related trademarks

CopyMark links this record to cited ยง2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Aug 12, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 12, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 16, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Jan 15, 2019EX5GSOU EXTENSION 5 GRANTEDโ€”
Jan 15, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGALโ€”
Jan 4, 2019EXT5SOU EXTENSION 5 FILEDโ€”
Jan 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 3, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Jun 29, 2018EX4GSOU EXTENSION 4 GRANTEDโ€”
Jun 29, 2018EXT4SOU EXTENSION 4 FILEDโ€”
Jun 29, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 15, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Nov 13, 2017EX3GSOU EXTENSION 3 GRANTEDโ€”
Nov 13, 2017EXT3SOU EXTENSION 3 FILEDโ€”
Nov 13, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 17, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
May 15, 2017EX2GSOU EXTENSION 2 GRANTEDโ€”
May 15, 2017EXT2SOU EXTENSION 2 FILEDโ€”
May 15, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 10, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILEDโ€”
Jan 6, 2017EX1GSOU EXTENSION 1 GRANTEDโ€”
Jan 6, 2017EXT1SOU EXTENSION 1 FILEDโ€”
Jan 6, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 12, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline โ€” usually six months from the notice date.
May 17, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILEDโ€”
May 17, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 27, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILEDโ€”
Mar 25, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTERโ€”
Mar 25, 2016XAECEXAMINER'S AMENDMENT ENTEREDโ€”
Mar 25, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILEDโ€”
Mar 25, 2016GNEAEXAMINERS AMENDMENT E-MAILEDโ€”
Mar 25, 2016CNEAEXAMINERS AMENDMENT -WRITTENโ€”
Mar 23, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 23, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 23, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 16, 2016DOCKASSIGNED TO EXAMINERโ€”
Dec 2, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTEREDโ€”
Nov 28, 2015NWAPNEW APPLICATION ENTEREDโ€”

Frequently asked questions

Related guidance